141 related articles for article (PubMed ID: 17961110)
1. Efficacy and safety of a once daily regimen with efavirenz, lamivudine, and didanosine, with and without food, as initial therapy for HIV Infection: the ELADI study.
Sánchez-Conde M; Palacios R; Sanz J; Rodríguez-Novoa S; Rivas P; Santos J; Sola J; Asensi V; de Mendoza C; Estrada V; Barreiro P; González-Lahoz J; Jiménez-Nacher I; Soriano V
AIDS Res Hum Retroviruses; 2007 Oct; 23(10):1237-41. PubMed ID: 17961110
[TBL] [Abstract][Full Text] [Related]
2. Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903.
Berenguer J; González J; Ribera E; Domingo P; Santos J; Miralles P; Angels Ribas M; Asensi V; Gimeno JL; Pérez-Molina JA; Terrón JA; Santamaría JM; Pedrol E;
Clin Infect Dis; 2008 Oct; 47(8):1083-92. PubMed ID: 18781872
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients.
Ribera E; Rodríguez-Pardo D; Rubio M; Soler A; Pedrol E; Blanco JL; González A; Crespo M; Falcó V; Ocaña I; Deig E; Miró JM; Pahissa A
Antivir Ther; 2005; 10(5):605-14. PubMed ID: 16152754
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and safety of didanosine, lamivudine and efavirenz versus zidovudine, lamivudine and efavirenz for the initial treatment of HIV-infected patients from the Spanish VACH cohort.
Crespo M; Ribera E; Suárez-Lozano I; Domingo P; Pedrol E; López-Aldeguer J; Muñoz A; Viladés C; Sánchez T; Viciana P; Teira R; García-Alcalde ML; Vergara A; Lozano F; Galindo MJ; Cosin J; Roca B; Terrón A; Geijo P; Vidal F; Garrido M;
J Antimicrob Chemother; 2009 Jan; 63(1):189-96. PubMed ID: 18988678
[TBL] [Abstract][Full Text] [Related]
5. Long-term effectiveness and safety of didanosine combined with lamivudine and efavirenz or nevirapine in antiretroviral-naive patients: a 9-year cohort study in Senegal.
Laurent C; Tchatchueng Mbougua JB; Ngom Guèye NF; Etard JF; Diouf A; Landman R; Molinari N; Girard PM; Sow PS; Ndoye I; Delaporte E;
Trop Med Int Health; 2011 Feb; 16(2):217-22. PubMed ID: 21087377
[TBL] [Abstract][Full Text] [Related]
6. Long-term assessment of didanosine, lamivudine, and efavirenz in antiretroviral-naive patients: 3-year follow-up.
Santos J; Palacios R; Lozano F; López M; Gálvez MC; de la Torres J; López-Cortés LF; Ríos MJ; Rivero A;
AIDS Res Hum Retroviruses; 2008 Jan; 24(1):24-6. PubMed ID: 18275344
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of didanosine and lamivudine both once daily plus indinavir in human immunodeficiency virus-infected patients.
de Mendoza C; Soriano V; Pérez-Olmeda M; Rodríguez-Rosado R; González-Lahoz J
J Hum Virol; 2000; 3(6):335-40. PubMed ID: 11100914
[TBL] [Abstract][Full Text] [Related]
8. Virological and immunological responses to a once-a-day antiretroviral regimen with didanosine, lamivudine and efavirenz.
Maggiolo F; Migliorino M; Maserati R; Pan A; Rizzi M; Provettoni G; Rizzi L; Suter F;
Antivir Ther; 2001 Dec; 6(4):249-53. PubMed ID: 11878406
[TBL] [Abstract][Full Text] [Related]
9. Simplicity and efficacy of a once-daily antiretroviral regimen with didanosine, lamivudine, and efavirenz in naïve patients: the VESD study.
Santos J; Palacios R; López M; Gálvez MC; Lozano F; de la Torre J; Ríos MJ; López-Cortés LF; Rivero A; Torres-Tortosa M;
HIV Clin Trials; 2005; 6(6):320-8. PubMed ID: 16566083
[TBL] [Abstract][Full Text] [Related]
10. Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infection.
Ruane P; Lang J; DeJesus E; Berger DS; Dretler R; Rodriguez A; Ward DJ; Lim ML; Liao Q; Reddy S; Clair MS; Vila T; Shaefer MS
HIV Clin Trials; 2006; 7(5):229-36. PubMed ID: 17162316
[TBL] [Abstract][Full Text] [Related]
11. Simplification therapy with once-daily didanosine, tenofovir and efavirenz in HIV-1-infected adults with viral suppression receiving a more complex antiretroviral regimen: final results of the EFADITE trial.
Barrios A; Negredo E; Domingo P; Estrada V; Labarga P; Asensi V; Morales D; Santos J; Clotet B; Soriano V;
Antivir Ther; 2005; 10(7):825-32. PubMed ID: 16312178
[TBL] [Abstract][Full Text] [Related]
12. Long-term safety and efficacy of a once-daily regimen of emtricitabine, didanosine, and efavirenz in HIV-infected, therapy-naive children and adolescents: Pediatric AIDS Clinical Trials Group Protocol P1021.
McKinney RE; Rodman J; Hu C; Britto P; Hughes M; Smith ME; Serchuck LK; Kraimer J; Ortiz AA; Flynn P; Yogev R; Spector S; Draper L; Tran P; Scites M; Dickover R; Weinberg A; Cunningham C; Abrams E; Blum MR; Chittick GE; Reynolds L; Rathore M;
Pediatrics; 2007 Aug; 120(2):e416-23. PubMed ID: 17646352
[TBL] [Abstract][Full Text] [Related]
13. Comparison of two once-daily regimens with a regimen consisting of nelfinavir, didanosine, and stavudine in antiretroviral therapy-naïve adults: 48-week results from the Antiretroviral Regimen Evaluation Study (ARES).
Lowe SH; Wensing AM; Hassink EA; ten Kate RW; Richter C; Schreij G; Koopmans PP; Juttmann JR; van der Tweel I; Lange JM; Borleffs JC
HIV Clin Trials; 2005; 6(5):235-45. PubMed ID: 16306030
[TBL] [Abstract][Full Text] [Related]
14. Poor efficacy and tolerability of stavudine, didanosine, and efavirenz-based regimen in treatment-naive patients in Senegal.
Canestri A; Sow PS; Vray M; Ngom F; M'boup S; Kane CT; Delaporte E; Gueye M; Peytavin G; Girard PM; Landman R;
MedGenMed; 2007 Oct; 9(4):7. PubMed ID: 18311357
[TBL] [Abstract][Full Text] [Related]
15. Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial.
DeJesus E; McCarty D; Farthing CF; Shortino DD; Grinsztejn B; Thomas DA; Schrader SR; Castillo SA; Sension MG; Gough K; Madison SJ;
Clin Infect Dis; 2004 Aug; 39(3):411-8. PubMed ID: 15307010
[TBL] [Abstract][Full Text] [Related]
16. Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12-week results from a randomized trial.
Maitland D; Moyle G; Hand J; Mandalia S; Boffito M; Nelson M; Gazzard B
AIDS; 2005 Jul; 19(11):1183-8. PubMed ID: 15990571
[TBL] [Abstract][Full Text] [Related]
17. Four year follow-up of simplification therapy with once-daily emtricitabine, didanosine and efavirenz in HIV-infected patients (ALIZE ANRS 099 trial).
Gallien S; Journot V; Rozenbaum W; Yéni P; Morlat P; Poizot-Martin I; Reynes J; Reliquet V; Leclercq P; Simon F; Chêne G; Molina JM;
J Antimicrob Chemother; 2011 Jan; 66(1):184-91. PubMed ID: 21036772
[TBL] [Abstract][Full Text] [Related]
18. Response to zidovudine/didanosine-containing combination antiretroviral therapy among HIV-1 subtype C-infected adults in Botswana: two-year outcomes from a randomized clinical trial.
Bussmann H; Wester CW; Thomas A; Novitsky V; Okezie R; Muzenda T; Gaolathe T; Ndwapi N; Mawoko N; Widenfelt E; Moyo S; Musonda R; Mine M; Makhema J; Moffat H; Essex M; Degruttola V; Marlink RG
J Acquir Immune Defic Syndr; 2009 May; 51(1):37-46. PubMed ID: 19282782
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and safety of simplification therapy with once-daily tenofovir, lamivudine, and efavirenz in HIV-1-infected patients with undetectable plasma viral load on HAART.
Arrizabalaga J; Arazo P; Aguirrebengoa K; García-Palomo D; Chocarro A; Labarga P; Muñoz-Sánchez MJ; Echevarría S; Oteo JA; Uriz J; Letona S; Fariñas MC; Peralta G; Pinilla J; Ferrer P; Alvarez ML; Iribarren JA
HIV Clin Trials; 2007; 8(5):328-36. PubMed ID: 17956834
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of a once-daily single-tablet regimen of tenofovir, lamivudine, and efavirenz assessed at 144 weeks among antiretroviral-naïve and experienced HIV-1-infected Thai adults.
Avihingsanon A; Maek-A-Nantawat W; Gatechompol S; Sapsirisavat V; Thiansanguankul W; Sophonphan J; Thammajaruk N; Ubolyam S; Burger DM; Ruxrungtham K
Int J Infect Dis; 2017 Aug; 61():89-96. PubMed ID: 28627427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]